About Genedit
Genedit is a company based in Berkeley (United States) founded in 2016. Genedit has raised $93.5 million across 5 funding rounds from investors including Lilly, SK and Korea Investment Holdings. The company has 34 employees as of December 31, 2024. Genedit offers products and services including NanoGalaxy. Genedit operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Berkeley, United States
- Employees 34 as on 31 Dec, 2024
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genedit Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$93.5 M (USD)
in 5 rounds
-
Latest Funding Round
$35 M (USD), Series B
Nov 20, 2024
-
Investors
Lilly
& 14 more
-
Employee Count
34
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genedit
Genedit offers a comprehensive portfolio of products and services, including NanoGalaxy.
Enables targeted delivery of genetic medicines for disease treatment.
People of Genedit
Unlock access to complete
Unlock access to complete
Funding Insights of Genedit
Genedit has successfully raised a total of $93.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genedit
Genedit has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, SK and Korea Investment Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested primarily in South Korean startups.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment holding firm established in Seoul in 2003.
|
Locked | Locked | Locked |
Investor details for Genedit
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genedit
Investment portfolio details for Genedit
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genedit
Detailed financials for Genedit
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genedit Comparisons
Peer comparison for Genedit
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genedit
Genedit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of precision therapeutics for dry AMD and rare genetic diseases
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
Detailed competitors of Genedit
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genedit
Complete news archive for Genedit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genedit
Genedit was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Genedit is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Genedit is a funded company, having raised a total of $93.5M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Genedit is 34.
Genedit was founded in 2016 and is headquartered in Berkeley, United States. Operations focus on the biotechnology sector, where non-viral, non-lipid polymer nanoparticles are developed for drug delivery. The NanoGalaxy platform is employed to transport genetic medicines to specific tissues, enabling disease treatment. This approach supports targeted therapies in genetic medicine applications.
Genedit's top competitors include Alnylam, BioMarin Pharmaceutical and Sirnaomics.
Genedit offers NanoGalaxy.
Genedit has 15 investors. Key investors include Lilly, SK, Korea Investment Holdings, DSC Investment, and KB Investment.